Research And Development Expense of NYMOX PHARMACEUTICAL CORP from 31 Dec 2015 to 31 Dec 2024

Taxonomy & unit
ifrs-full: USD
Summary
NYMOX PHARMACEUTICAL CORP annual and quarterly Research And Development Expense in USD history and change rate from 31 Dec 2015 to 31 Dec 2024.
  • NYMOX PHARMACEUTICAL CORP Research And Development Expense for the quarter ending 30 Sep 2024 was $511,000, a 23% decline year-over-year.
  • NYMOX PHARMACEUTICAL CORP annual Research And Development Expense for 2024 was $3,280,000, a 18% decline from 2023.
  • NYMOX PHARMACEUTICAL CORP annual Research And Development Expense for 2023 was $3,994,000, a 5.9% increase from 2022.
  • NYMOX PHARMACEUTICAL CORP annual Research And Development Expense for 2022 was $3,773,000, a 43% decline from 2021.
Source SEC data
View on sec.gov
Research And Development Expense, Annual (USD)
Research And Development Expense, YoY Annual Change (%)
Research And Development Expense, Trailing 12 Months (USD)
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Change (%)

NYMOX PHARMACEUTICAL CORP Annual Research And Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,280,000 -$714,000 -18% 01 Jan 2024 31 Dec 2024 20-F 03 Jun 2025 2024 FY
2023 $3,994,000 +$221,000 +5.9% 01 Jan 2023 31 Dec 2023 20-F 03 Jun 2025 2024 FY
2022 $3,773,000 -$2,885,000 -43% 01 Jan 2022 31 Dec 2022 20-F 03 Jun 2025 2024 FY
2021 $6,658,000 -$1,462,000 -18% 01 Jan 2021 31 Dec 2021 20-F 29 Aug 2024 2023 FY
2020 $8,120,000 +$743,000 +10% 01 Jan 2020 31 Dec 2020 20-F 02 May 2023 2022 FY
2019 $7,377,000 +$700,000 +10% 01 Jan 2019 31 Dec 2019 20-F 30 Mar 2022 2021 FY
2018 $6,677,000 -$1,197,000 -15% 01 Jan 2018 31 Dec 2018 20-F 29 Mar 2021 2020 FY
2017 $7,874,000 +$1,076,000 +16% 01 Jan 2017 31 Dec 2017 20-F 30 Mar 2020 2019 FY
2016 $6,798,000 -$1,852,000 -21% 01 Jan 2016 31 Dec 2016 20-F 29 Mar 2019 2018 FY
2015 $8,650,000 01 Jan 2015 31 Dec 2015 20-F 30 Mar 2018 2017 FY

NYMOX PHARMACEUTICAL CORP Quarterly Research And Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $511,000 -$150,000 -23% 01 Jul 2024 30 Sep 2024 6-K 02 Jan 2025 2024 Q3
Q4 2023 $3,994,000 $2,019,000 +$4,282,000 01 Oct 2023 31 Dec 2023 20-F 03 Jun 2025 2024 FY
Q3 2023 $288,000 $661,000 -$231,000 -26% 01 Jul 2023 30 Sep 2023 6-K 02 Jan 2025 2024 Q3
Q2 2023 $57,000 $594,000 -$216,000 -27% 01 Apr 2023 30 Jun 2023 6-K 14 Aug 2023 2023 Q2
Q1 2023 $159,000 $720,000 -$3,614,000 -83% 01 Jan 2023 31 Mar 2023 6-K 12 May 2023 2023 Q1
Q4 2022 $3,773,000 $2,263,000 -$3,589,000 -271% 01 Oct 2022 31 Dec 2022 20-F 03 Jun 2025 2024 FY
Q3 2022 $7,362,000 $892,000 -$947,000 -51% 01 Jul 2022 30 Sep 2022 6-K 15 Nov 2023 2023 Q3
Q2 2022 $8,309,000 $810,000 -$1,258,000 -61% 01 Apr 2022 30 Jun 2022 6-K 14 Aug 2023 2023 Q2
Q1 2022 $9,567,000 $4,334,000 +$2,909,000 +204% 01 Jan 2022 31 Mar 2022 6-K 12 May 2023 2023 Q1
Q4 2021 $6,658,000 $1,326,000 +$152,000 +13% 01 Oct 2021 31 Dec 2021 20-F 29 Aug 2024 2023 FY
Q3 2021 $6,506,000 $1,839,000 -$1,396,000 -43% 01 Jul 2021 30 Sep 2021 6-K/A 16 Nov 2022 2022 Q3
Q2 2021 $7,902,000 $2,068,000 -$88,000 -4.1% 01 Apr 2021 30 Jun 2021 6-K 15 Aug 2022 2022 Q2
Q1 2021 $7,990,000 $1,425,000 -$130,000 -8.4% 01 Jan 2021 31 Mar 2021 6-K 13 May 2022 2022 Q1
Q4 2020 $8,120,000 $1,174,000 -$630,000 -35% 01 Oct 2020 31 Dec 2020 20-F 02 May 2023 2022 FY
Q3 2020 $8,750,000 $3,235,000 +$1,727,000 +115% 01 Jul 2020 30 Sep 2020 6-K 12 Nov 2021 2021 Q3
Q2 2020 $7,023,000 $2,156,000 -$180,000 -7.7% 01 Apr 2020 30 Jun 2020 6-K 13 Aug 2021 2021 Q2
Q1 2020 $7,203,000 $1,555,000 -$174,000 -10% 01 Jan 2020 31 Mar 2020 6-K 14 May 2021 2021 Q1
Q4 2019 $7,377,000 $1,804,000 +$287,000 +19% 01 Oct 2019 31 Dec 2019 20-F 30 Mar 2022 2021 FY
Q3 2019 $7,090,000 $1,508,000 -$146,000 -8.8% 01 Jul 2019 30 Sep 2019 6-K 13 Nov 2020 2020 Q3
Q2 2019 $7,236,000 $2,336,000 +$787,000 +51% 01 Apr 2019 30 Jun 2019 6-K 14 Aug 2020
Q1 2019 $6,449,000 $1,729,000 -$228,000 -12% 01 Jan 2019 31 Mar 2019 6-K 14 May 2020 2020 Q1
Q4 2018 $6,677,000 $1,517,000 -$943,000 -38% 01 Oct 2018 31 Dec 2018 20-F 29 Mar 2021 2020 FY
Q3 2018 $7,620,000 $1,654,000 -$499,000 -23% 01 Jul 2018 30 Sep 2018 6-K 13 Nov 2019 2019 Q3
Q2 2018 $8,119,000 $1,549,000 -$36,000 -2.3% 01 Apr 2018 30 Jun 2018 6-K 14 Aug 2019 2019 Q2
Q1 2018 $8,155,000 $1,957,000 +$281,000 +17% 01 Jan 2018 31 Mar 2018 6-K 15 May 2019 2019 Q1
Q4 2017 $7,874,000 $2,460,000 01 Oct 2017 31 Dec 2017 20-F 30 Mar 2020 2019 FY
Q3 2017 $2,153,000 01 Jul 2017 30 Sep 2017 6-K 13 Nov 2018 2018 Q3
Q2 2017 $1,585,000 01 Apr 2017 30 Jun 2017 6-K 13 Aug 2018 2018 Q2
Q1 2017 $1,676,000 01 Jan 2017 31 Mar 2017 6-K 15 May 2018 2018 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.